Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

B-902

Supelco

Buprenorphine solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C29H41NO4
Numero CAS:
52485-79-7
Peso molecolare:
467.64
Numero CE:
200-659-6
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

Concentrazione

100 μg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

2-8°C

Stringa SMILE

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4CC7CC7)c56

InChI

1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
RMRJXGBAOAMLHD-IHFGGWKQSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Sold under the trade names Buprenex®, Subutex® and Suboxone®, buprenorphine is an opiate drug used to treat opioid addiction and moderate acute pain. This Certified Spiking Solution® standard is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or pharmaceutical research.

Applicazioni


  • Research on Addiction and Implementation Challenges: Buprenorphine solutions have been crucial in studies exploring how systemic barriers affect the implementation of addiction treatments during concurrent public health crises, offering insights valuable for policy and practice adjustments in healthcare systems (Sharp et al., 2023).

  • Evaluating Patient-Important Measures in Opioid Use Disorder Treatments: Buprenorphine is used extensively to evaluate patient-important outcomes in medication-assisted treatment programs for opioid use disorders, aiding in the assessment of long-term recovery metrics and treatment efficacy (Reed et al., 2023).

  • Web-Based Substance Use Epidemiology Research: Buprenorphine research solutions are instrumental in developing web-based ontologies for tracking and analyzing drug abuse trends, providing a foundational tool for public health surveillance and policy-making in substance abuse epidemiology (Lokala et al., 2022).

  • Clinical Studies in Veterinary Medicine: Buprenorphine solutions are employed in veterinary medicine to assess the efficacy of transdermal applications for managing postoperative pain in animals, demonstrating its versatility and effectiveness across different biological systems (Clark et al., 2022).

  • Pain Management in Geriatric Orthopedics: The use of transdermal buprenorphine for managing pain following femur fractures in elderly patients highlights its critical role in improving postoperative care and enhancing recovery outcomes in geriatric orthopedics (Davies et al., 2022).

Note legali

Buprenex is a registered trademark of Reckitt & Colman (Overseas) Ltd
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Suboxone is a registered trademark of RB Pharmaceuticals Limited
Subutex is a registered trademark of RB Pharmaceuticals Limited

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

B-035

Buprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-044

Buprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-901

Buprenorphine-D4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-908

Buprenorphine-D4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-071

Pain Management Multi-component Opiate Mixture-13 solution, 100 μg/mL each component (10 μg/mL Fentanyl), ampule of 1.0 mL, certified reference material, Cerilliant®

N-045

Norbuprenorphine glucuronide solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-059

Norbuprenorphine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-912

Norbuprenorphine solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-920

Norbuprenorphine-D3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

N-921

Norbuprenorphine-D3 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-100

Buprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-101

Buprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-145

Norbuprenorphine-D9 solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

N-146

Norbuprenorphine-D9-3-beta-D-glucuronide solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 3

1 of 3

(±)-Methadone solution 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-007

(±)-Methadone solution

Myristyltrimethylammonium bromide ≥99%

Sigma-Aldrich

T4762

Myristyltrimethylammonium bromide

Sodio cloruro 0.9% in water, BioXtra, suitable for cell culture

Sigma-Aldrich

S8776

Sodio cloruro

K Wahle et al.
MMW Fortschritte der Medizin, 155 Suppl 1, 25-31 (2013-05-18)
Chronic pain in the elderly is common. Especially in the elderly inadequate treatment of pain can cause significant functional impairmentand deterioration of qualityof life. Theaim of this post-marketing surveillance study was to collect data from clinical practice on the analgesic
O Bouab et al.
Revue medicale de Bruxelles, 34(3), 132-140 (2013-08-21)
Assess the effectiveness of hospital detoxification of opiate substitution treatment (OST) in patients who failed to withdraw as outpatients. Retrospective study, conducted among patients admitted for withdrawal of OST in an addiction unit between 2005 and 2011. Referent physicians were
Jatinder Mohan Chawla et al.
Journal of opioid management, 9(1), 35-41 (2013-05-28)
Tramadol is a synthetic opiate and a centrally acting weak m-opioid receptor agonist. The potential advantages of tramadol include ease of administration, low abuse potential, and being nonscheduled. This study compared tramadol and buprenorphine for controlling withdrawal symptoms in patients
Johan Menten et al.
Cancer investigation, 31(6), 412-420 (2013-06-14)
Many head and neck cancer (HNC) patients experience painful therapy-related mucositis and dermatitis. This prospective observational study evaluated transdermal buprenorphine use in HNC patients to relieve treatment-related pain. During treatment with paracetamol or tramadol, visual analogue scale (VAS)-pain scores >30/100
Karen L Cropsey et al.
Journal of addiction medicine, 7(3), 210-215 (2013-04-24)
This project sought to demonstrate the feasibility and acceptability of providing on-site buprenorphine treatment to individuals under community corrections supervision. Seventeen women and 13 men were enrolled on-site over a 2-week period at a community corrections location. Study participants received
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.